A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

ID#: NCT06693531

Age: 1 year - 66+

Gender: All

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: November 22, 2024

End Date: May 09, 2030

Contact Information:
Clinical Trials Administrator
844-734-6643
Summary: This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: - How EoE makes one feel - EoE signs and/or symptoms, eg, how difficult it is to swallow - How EoE affects quality-of-life - How EoE impacts aspects of daily life - How EoE symptoms have changed throughout the study
Eligibility: Key

Inclusion Criteria:

1. Initiating treatment with DUPIXENT® for EoE according to the USPI

2. Participants aged ≥12 years and caregivers or legal guardians of participants aged <12 years must be able to understand and complete registry-related questionnaires Key

Exclusion Criteria:

1. Patients who have a contraindication to DUPIXENT® according to the USPI

2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment

3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator) NOTE: Other protocol defined inclusion/exclusion criteria apply
Find a Clinical Trial Find Cancer Clinical Trials